Moleculin Biotech furnishes Oct 16, 2026 investor presentation under Reg FD; exhibit text not included

Moleculin Biotech, Inc.

Moleculin Biotech (MBRX) disclosed a corporate investor presentation dated October 16, 2026 as Exhibit 99.1 under Item 7.01 Regulation FD.
Filing states the presentation is posted on the Company's website, but the exhibit supplied contains no readable content beyond the 'Exhibit 99.1' header.
No financial results, clinical trial data, guidance, or transaction terms appear anywhere in the filing body; no specific facts can be extracted.
Signed by Jonathan P. Foster on October 16, 2026; company address listed as 5300 Memorial Drive, Suite 950, Houston, TX 77007.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.